Abstracts tagged "Lung Disease"

Abstract Number: 2922 • 2014 ACR/ARHP Annual Meeting
Association of Single Nucleotide Polymorphisms of PADI4 Gene with Susceptibility to Rheumatoid Arthritis-Related Lung Disease
Seong-Wook Kang¹, Seung-Taek Song¹, Song Soo Kim², Ji Young Kim¹, So Young Lee¹, Su-Jin Yoo³, In-Seol Yoo¹, Jinhyun Kim¹ and Seung-Cheol Shim¹, ¹Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Radiology, Chungnam National University School of Medicine, Daejeon, South Korea, ³Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose Rheumatoid arthritis (RA) causes a myriad of pulmonary complications, including bronchiolitis and bronchiectasis, pleuritis, and interstitial lung disease (ILD). Recently, several studies have shown…
Abstract Number: 2702 • 2014 ACR/ARHP Annual Meeting
Key Roles for Mir-155 and Mir-21 in Progressive Lung Fibrosis Associated with Systemic Sclerosis (SSc-ILD)
Romy Christmann¹, Percival D Sampaio-Barros², Claudia Borges³, Carlos Carvalho⁴, Ronaldo A Kairalla⁵, Edwin R. Parra⁶, Giuseppina Stifano⁷, Avi Spira⁸, Robert W. Simms⁹, Vera L. Capelozzi⁶ and Robert Lafyatis¹⁰, ¹Rheumatology, Arthritis Center/Rheumatology, Boston, MA, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology, CEUMA University, Sao Luis do Maranhao, Brazil, ⁴Pulmonology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁵Division of Pulmonology - Heart Institute (InCor) - Medical School, University of Sao Paulo, Sao Paulo, Brazil, ⁶Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁷Rheumatology, Boston University Medical Center, Boston, MA, ⁸Boston University School of Medicine, Boston, MA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Arthritis Center, Boston University, Boston, MA
Background/Purpose We have already reported that macrophage activation, and up-regulation of TGF-beta- and interferon-regulated genes are involved in progressive SSc-ILD. Micro-rnas (miRNA) are a class…
Abstract Number: 1259 • 2014 ACR/ARHP Annual Meeting
A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody
Shinji Sato¹, Akihiro Murakami², Akiko Kuwajima³, Kazuhiko Takehara⁴, Tsuneyo Mimori⁵, Atsushi Kawakami⁶, Michiaki Mishima⁷, Takafumi Suda⁸, Mariko Seishima⁹, Manabu Fujimoto¹⁰ and Masataka Kuwana¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, ³Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, ⁴Dermatology, Kanazawa University, Kanazawa, Japan, ⁵Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁶Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁸Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁹Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, ¹⁰Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM) and…
Abstract Number: 755 • 2014 ACR/ARHP Annual Meeting
Increased Degradation of BMPR2 in a TGFβ Dependent Transgenic Mouse Model of Scleroderma with Susceptibility to Pulmonary Arterial Hypertension
Adrian J Gilbane¹, Emma C. Derrett-Smith², Andrew Pearce³, Christopher P Denton⁴ and Alan M. Holmes⁵, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ³Respiratory Disease Area, Novartis, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom
Background/Purpose Scleroderma patients are susceptible to development of pulmonary arterial hypertension (PAH) that has similarities to some forms of heritable PAH. The basis for this…
Abstract Number: 732 • 2014 ACR/ARHP Annual Meeting
Predictors of Inpatient Mortality in Patients with Systemic Sclerosis: A Case Control Study
Shiv Tej Sehra¹, Chris T. Derk¹, Andrew Kelly² and Joshua Baker³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine, Pennsylvania Hospital, Philadelphia, PA, ³Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose There are few published studies on predictors of inpatient mortality in patients with systemic sclerosis (SSc). Knowledge of these predictors is important for early…
Abstract Number: 437 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Heat Shock Protein 90 Antibodies Identified in Bronchoalveolar Lavage Fluid Are a Marker of Lung-Specific Immune Responses
Lisa Harlow¹, Bernadette Gochuico², Ivan Rosas³, Tracy Doyle⁴, Juan Osorio⁴, Timothy Travers⁵, Carlos Camacho⁶, Chester V. Oddis⁷ and Dana P. Ascherman⁸, ¹Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ²Medical Genetics Branch, National Institutes of Health, Bethesda, MD, ³Medicine/Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, ⁶Compuational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose . Previous work has demonstrated an association between serum anti-citrullinated HSP90 antibodies and rheumatoid arthritis-associated interstitial lung disease (RA-ILD). To further investigate this potential…
Abstract Number: 413 • 2014 ACR/ARHP Annual Meeting
Association of Antinuclear Antibodies with Lung Disease, Malignancy and Joint Replacement in Rheumatoid Arthritis
Reshmi Raveendran¹, Bobby Kwanghoon Han², Quan-Zhen Li³ and Nancy J. Olsen¹, ¹Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ²Rheumatology, Cooper Medical School of Rowan University, Camden, NJ, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose Antinuclear antibodies (ANAs) are present in a significant proportion of patients with rheumatoid arthritis (RA). Positivity for ANA in RA has been associated with…
Abstract Number: 236 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic Fibrosis
Joshua Baker¹, Putman Melissa², Karen Herlyn³, Angela S. Pizzo⁴, Allen Lapey⁵, Joel Finklestein² and Peter A. Merkel⁶, ¹Medicine/Rheumatology, Philadelphia VA Medical Center, Philadelphia, PA, ²Harvard University, Boston, MA, ³Department of Rheumatology, University Hospital Schleswig-Holstein, Lübeck, Germany, ⁴Mercy Hospital, Portland, ME, ⁵Cystic Fibrosis Center and Division of Pediatric Pulmonology, Massachusetts General Hospital, Boston, MA, ⁶University of Pennsylvania, Philadelphia, PA
Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic FibrosisBackground/Purpose Cystic Fibrosis (CF) is associated with an increased risk…
Abstract Number: 147 • 2014 ACR/ARHP Annual Meeting
US Lung Examination in SSc Patients: A Comparison of Two Different Scoring Systems
Andrea Delle Sedie¹, Cristina Lodato¹, Elisa Cioffi¹, Linda Carli², Stefano Bombardieri¹ and Lucrezia Riente¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²GenOMeC PhD, University of Siena, Siena, Italy
Background/Purpose Systemic sclerosis (SSc) is a disease characterized by a progressive fibrosis of the skin and internal organs, which can lead to death. Lung involvement…
Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Thomas Frauenfelder¹, Anna Winklehner¹, Thi Dan Linh Nguyen¹, Rucsandra Dobrota^2,3, Stephan Baumüller¹, Britta Maurer² and Oliver Distler², ¹Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
Abstract Number: 2567 • 2013 ACR/ARHP Annual Meeting
Cadherin-11 Regulates Pulmonary Fibrosis In Bleomycin-Induced Lung Injury
Mesias Pedroza, Anuh T. George and Sandeep K. Agarwal, Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Pulmonary fibrosis (PF) is the leading cause of death in systemic sclerosis. Pathologically, PF is characterized by an aberrant wound healing repair mechanism leading…
Abstract Number: 2070 • 2013 ACR/ARHP Annual Meeting
Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl tRNA Synthetase Antibody-Associated Interstitial Lung Disease
Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Hidenaga Kawasumi, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) are often complicated with interstitial lung disease (ILD). In PM/DM, complication with ILD is associated with anti-aminoacyl-tRNA synthetase (ARS),…
Abstract Number: 2076 • 2013 ACR/ARHP Annual Meeting
Oxidation Products Of Arachidonic Acid and Linoleic Acid Are Increased In High Density Lipoprotein From Patients With Dermatomyositis and Polymyositis
Christina Charles-Schoeman¹, Yuen Yin Lee¹, Ani Shahbazian¹, David Meriwether², Geraldine Navarro¹, John D. FitzGerald¹ and Srinivasa T. Reddy², ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Oxidation products of arachidonic acid and linoleic acid including hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadecadienoic acids (HODEs), respectively, play an important role in the…
Abstract Number: 2077 • 2013 ACR/ARHP Annual Meeting
Inflammatory Lung Disease a Potential Risk Factor For Onset Of Inflammatory Myopathies
Ingrid E. Lundberg¹, Sevim Barbasso Helmers² and Lars Alfredsson³, ¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Although the etiology of inflammatory myopathies is unclear, there are data indicating that myositis occurs as a result of complex interactions between genes and…
Abstract Number: 2079 • 2013 ACR/ARHP Annual Meeting
Serum Interferon α, β and Interleukin-18 Are Associated With Disease Activity Of Rapidly Progressive Interstitial Lung Disease In Patients With Clinical Amyopathic Dermatomyositis
Shinji Sato¹, Noriko Sasaki¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: It is well known that rapidly progressive interstitial lung disease (RP-ILD) in patients with dermatomyositis (DM) is associated with poor outcome. Previous findings suggested…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].